Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICIs and Anti-VEGF with or without Interventional Therapy for Advanced HCC
NCT07157969Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective Response Rate at 12 months. Started Feb 2025; status: recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07157969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07157969.